Apogee Therapeutics, Inc.
APGEDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001974640
Apogee Therapeutics, Inc. was delisted in 2026; its insiders filed their last Form 4 on Sep 3, 2026; 288 institutions reported holding it in 13F filings for Q2 2026, worth $8.93B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 3
- Last 90 days, $4.14M in total
- 13F holders
- 288
- Q2 2026, +68 vs. previous quarter
- 13F value
- $8.93B
- Reported value at the end of Q2 2026
- Superinvestors holding
- 1
- At the end of Q2 2026
Superinvestors holding APGE, Q2 2026
1 superinvestor reports holding Apogee Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
1.0%
Apogee Therapeutics, Inc.'s share of the portfolio
- Shares
- 564,500
- Value
- $74.9M
Latest insider trades
Open-market purchases and sales by Apogee Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 (view filing)8:00 PM ET | Aug 5 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $134.17 | −$737.9K | −3.2%168.5K after | 10b5-1 |
| Jul 10, 2026 (view filing)8:00 PM ET | Jul 8 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $133.63 | −$2.67M | −2.0%996.0K after | 10b5-1 |
| Jul 2, 2026 (view filing)8:13 PM ET | Jul 1 | 1 day | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $132.74 | −$730.1K | −3.0%177.9K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −26.4K | $132.60 | −$3.50M | −12.8%179.2K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −80.0K | $132.54 | −$10.6M | −7.3%1.02M after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 10 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $83.38 | −$1.67M | −1.8%1.10M after | 6 lots10b5-1 |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $78.71 | −$432.9K | −2.6%205.6K after | 10b5-1 |
| May 15, 2026 (view filing) | May 13 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $82.09 | −$1.64M | −1.8%1.12M after | 2 lots10b5-1 |
| May 8, 2026 (view filing) | May 6 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $84.14 | −$462.8K | −2.6%207.0K after | 2 lots10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | Henderson JaneChief Financial Officer | SSale | −2.00K | $82.04 | −$164.1K | −1.1%173.4K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Apogee Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| VR Adviser, LLC | 8,493,321 | $1.13B | 34.18% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,507,032 | $730.9M | 0.01% | +1,421,381+34.8% | Added |
| HBK Investments L P | 2,850,000 | $378.3M | 4.40% | +2,850,000 | New |
| Vanguard Capital Management LLC | 2,572,119 | $341.4M | 0.01% | +70,024+2.8% | Added |
| FMR LLC | 2,493,137 | $330.9M | 0.01% | −6,769,154−73.1% | Reduced |
| State Street Corp | 2,297,743 | $305.0M | 0.01% | +134,779+6.2% | Added |
| Driehaus Capital Management LLC | 1,740,101 | $231.0M | 1.34% | −180,699−9.4% | Reduced |
| Goldman Sachs Group Inc | 1,693,341 | $224.8M | 0.02% | +1,040,751+159.5% | Added |
| Balyasny Asset Management LLC | 1,665,102 | $221.0M | 0.40% | +1,226,448+279.6% | Added |
| Glazer Capital, LLC | 1,641,042 | $217.8M | 5.37% | +1,641,042 | New |